Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

E 6742

Next Previous
Drug Profile

E 6742

Alternative Names: E-6742

Latest Information Update: 20 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Inc
  • Developer Eisai Co Ltd; Eisai Inc
  • Class Antineoplastics
  • Mechanism of Action Toll-like receptor 7 antagonists; Toll-like receptor 8 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Systemic lupus erythematosus
  • No development reported Autoimmune disorders
  • Discontinued Cancer; Neurological disorders

Most Recent Events

  • 14 Nov 2024 Efficacy, pharmacodynamics and adverse events data from a phase I/II trial in Systemic lupus erythematosus presented at the ACR Convergence 2024
  • 12 Jun 2024 Efficacy, pharmacokinetics and adverse events data from a phase I/II trial in Systemic lupus erythematosus presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
  • 28 Jan 2024 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in Japan (PO, Tablet)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top